Data and Safety Monitoring Committee

Genticel to continue per protocol its phase II study with ProCervix after review by DSMB

Thursday, January 29, 2015

Genticel, a French biotechnology company and developer of therapeutic vaccines, has announced that the Data and Safety Monitoring Board (DSMB), an independent committee of experts which monitors safety data every six months during a study, met as scheduled on Jan. 22. It recommended the RHEIA-VAC study proceed without any modifications. The DSMB already had made the same recommendation during the first review on July 1, 2014.

[Read More]

Anne Lindblad promoted to president and CEO of EMMES

Monday, August 12, 2013

EMMES has promoted executive vice president Dr. Anne Lindblad to president and chief executive officer. Lindblad replaces Dr. Donald (Don) Stablein, who has been named past president. Stablein, who joined the company in 1980, has been president/CEO since 1992. In his new role as past president, he will continue to provide project support and will be an ambassador for EMMES.

[Read More]